BRIEF

on CompuGroup Medical SE & Co. KGaA (isin : DE000A288904)

CompuGroup Medical Reports First Quarter Financials for 2024

CompuGroup Medical SE & Co. KGaA announced its financial results for the first quarter of 2024, showing a decrease of 2% in group revenues compared to the prior year, influenced by one-off effects in the Telematics Infrastructure. However, organic growth stood at 3% when adjusted for these one-offs. Recurring revenues increased by 7% to EUR 213 million, accounting for 75% of total revenue, with adjusted EBITDA rising 1% to EUR 61 million, and adjusted EPS increasing to EUR 0.47.

In Germany and France, the company reports significant progress in the digitization of healthcare, with a substantial increase in electronic prescriptions and digital health documents. This advancement has contributed to a 3% organic revenue growth in the AIS segment. The HIS segment saw a 7% growth, driven by ongoing projects related to the Hospital Future Act. Meanwhile, the PCS segment revenues slightly declined due to previous one-off hardware sales in Italy.

CompuGroup Medical has decided to focus on annual rather than mid-term financial guidance, projecting organic revenue growth between 4% and 6% for 2024, with adjusted EBITDA projected to range between EUR 270 million and EUR 310 million. This approach reflects a cautious but optimistic outlook for ongoing growth and stability in core markets.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all CompuGroup Medical SE & Co. KGaA news